Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

Concepción Fernández-Rodríguez; Antonio Salar; Alfons Navarro; Eva Gimeno; Silvia Pairet; Laura Camacho; Mariana Ferraro; Sergi Serrano; Carles Besses; Beatriz Bellosillo; Blanca Sanchez-Gonzalez

doi:10.3109/10428194.2015.1063143

Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

Concepción Fernández-Rodríguez, Antonio Salar, Alfons Navarro, Eva Gimeno, Silvia Pairet, Laura Camacho, Mariana Ferraro, Sergi Serrano, Carles Besses, Beatriz Bellosillo, Blanca Sanchez-Gonzalez

Research output: Contribution to journal › Article › Research › peer-review

10 Citations (Scopus)

Abstract

© 2015 © 2015 Informa UK, Ltd. Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC-and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.

Original language	English
Pages (from-to)	692-699
Journal	Leukemia and Lymphoma
Volume	57
Issue number	3
DOIs	https://doi.org/10.3109/10428194.2015.1063143
Publication status	Published - 3 Mar 2016

Keywords

Bendamustine
Diffuse large B-cell lymphoma
Histone deacetylase inhibitor
TP53
Vorinostat

Access to Document

10.3109/10428194.2015.1063143

Cite this

@article{9cb55631a1674273b6d5f1041a89263d,

title = "Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells",

abstract = "{\textcopyright} 2015 {\textcopyright} 2015 Informa UK, Ltd. Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC-and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.",

keywords = "Bendamustine, Diffuse large B-cell lymphoma, Histone deacetylase inhibitor, TP53, Vorinostat",

author = "Concepci{\'o}n Fern{\'a}ndez-Rodr{\'i}guez and Antonio Salar and Alfons Navarro and Eva Gimeno and Silvia Pairet and Laura Camacho and Mariana Ferraro and Sergi Serrano and Carles Besses and Beatriz Bellosillo and Blanca Sanchez-Gonzalez",

year = "2016",

month = mar,

day = "3",

doi = "10.3109/10428194.2015.1063143",

language = "English",

volume = "57",

pages = "692--699",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "3",

}

TY - JOUR

T1 - Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

AU - Fernández-Rodríguez, Concepción

AU - Salar, Antonio

AU - Navarro, Alfons

AU - Gimeno, Eva

AU - Pairet, Silvia

AU - Camacho, Laura

AU - Ferraro, Mariana

AU - Serrano, Sergi

AU - Besses, Carles

AU - Bellosillo, Beatriz

AU - Sanchez-Gonzalez, Blanca

PY - 2016/3/3

Y1 - 2016/3/3

N2 - © 2015 © 2015 Informa UK, Ltd. Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC-and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.

AB - © 2015 © 2015 Informa UK, Ltd. Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC-and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.

KW - Bendamustine

KW - Diffuse large B-cell lymphoma

KW - Histone deacetylase inhibitor

KW - TP53

KW - Vorinostat

U2 - 10.3109/10428194.2015.1063143

DO - 10.3109/10428194.2015.1063143

M3 - Article

VL - 57

SP - 692

EP - 699

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -

Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

Abstract

Keywords

Access to Document

Fingerprint

Cite this